aTYR PHARMA (ATYR) Interest & Investment Income (2015 - 2026)
aTYR PHARMA's (ATYR) quarterly Interest & Investment Income came in at -$9000.0 in Q2 2025, up 10.0% YoY from -$8181.8 in Q2 2024, and up 65.38% on a QoQ basis from -$26000.0 in Q1 2025.
aTYR PHARMA (ATYR) Interest & Investment Income (2015 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 11 years of Interest & Investment Income data on file, last reported at -$9000.0 in Q2 2025.
- Quarterly Interest & Investment Income rose 10.0% year-over-year to -$9000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$129000.0 (down 2250.0% YoY) and the FY2021 annual result came in at -$220000.0, changed N/A from the prior year.
- Interest & Investment Income improved to -$9000.0 in Q2 2025, from -$26000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $185000.0 in Q1 2023 to a low of -$496000.0 in Q1 2022.
- A 5-year average of -$50384.6 and a median of -$14000.0 in 2021 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 1862.5% in 2022, down 3442.86% in 2022.
- Tracing ATYR's Interest & Investment Income over 5 years: stood at -$194000.0 in 2021, then soared by 172.68% to $141000.0 in 2022, then sank by 160.28% to -$85000.0 in 2023, then jumped by 88.24% to -$10000.0 in 2024, then climbed by 10.0% to -$9000.0 in 2025.
- The last three Interest & Investment Income figures came in at -$9000.0 (Q2 2025), -$26000.0 (Q1 2025), and -$10000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -26,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -84,000.00 |
| Jun 30, 2023 | -85,000.00 |
| Mar 31, 2023 | 185,000.00 |
| Sep 30, 2022 | 141,000.00 |
| Jun 30, 2022 | -51,000.00 |
| Mar 31, 2022 | -496,000.00 |
| Dec 31, 2021 | -194,000.00 |
| Sep 30, 2021 | -8,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | -14,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | -13,000.00 |
| Jun 30, 2019 | 8,000.00 |
| Mar 31, 2019 | 20,000.00 |
| Dec 31, 2018 | -3,000.00 |